Financial Results Summary

Consolidated Financial Results (Quarter Ended 30 June 2026)

  • Revenue from Operations: ₹1,431.88 crore
  • Other Income: ₹56.31 crore
  • Total Income: ₹1,488.19 crore
  • Total Expenses: ₹1,187.68 crore
  • Profit Before Tax: ₹300.51 crore
  • Tax Expense: ₹72.08 crore (Current tax: ₹61.73 crore, Deferred tax: ₹10.35 crore)
  • Net Profit After Tax: ₹228.43 crore
  • Total Comprehensive Income: ₹234.01 crore
  • Earnings Per Share (Basic & Diluted): ₹4.55
  • Paid-up Equity Share Capital: ₹50.45 crore (Face value Re. 1 each)

Standalone Financial Results (Quarter Ended 30 June 2026)

  • Revenue from Operations: ₹1,274.26 crore
  • Other Income: ₹58.45 crore
  • Total Income: ₹1,332.71 crore
  • Total Expenses: ₹1,038.64 crore
  • Profit Before Tax: ₹294.07 crore
  • Tax Expense: ₹70.65 crore (Current tax: ₹60.15 crore, Deferred tax: ₹10.50 crore)
  • Net Profit After Tax: ₹223.42 crore
  • Total Comprehensive Income: ₹226.60 crore
  • Earnings Per Share (Basic & Diluted): ₹4.43
  • Paid-up Equity Share Capital: ₹50.45 crore (Face value Re. 1 each)

Segment Performance (Consolidated)

  • Carbon materials and chemicals: Revenue ₹1,278.90 crore, Segment profit ₹262.56 crore
  • Power: Revenue ₹31.88 crore, Segment profit ₹28.10 crore
  • Others: Revenue ₹143.89 crore, Segment profit ₹1.15 crore

Capex Approvals

1. Anthraquinone and Carbazole Capacity Expansion

  • Additional Capex: ₹128 crores
  • Purpose: Enhance production capacity from 2600 MTPA to 5300 MTPA
  • Funding: Primarily through internal accruals
  • Implementation: Two phases
  • Phase 1: 2600 MTPA capacity to be commissioned by Q2 FY27
  • Phase 2: 2700 MTPA capacity expected by Q2 FY28
  • Note: No change in company's overall production capacity
  • Reference: Builds on previous approval dated 13 January 2025 for ₹120 crores capex

2. Carbon Nano Tubes (CNT) Manufacturing Facility

  • Capex: ₹70 crores
  • Location: West Bengal
  • Technology: In-house developed through R&D efforts
  • Capacity: 200 MTPA annual production
  • Funding: Internal accruals
  • Commissioning: Expected by Q4 FY27
  • Significance: India's first CNT manufacturing facility with in-house technology
  • Applications: Electric vehicles (lithium-ion batteries), electronics, composites, energy storage, industrial coatings
  • Strategic Impact: Reduces import dependency, aligns with Atmanirbhar Bharat vision

3. Super Speciality Carbon Black (SSCB)

  • Capex: ₹170 crores
  • Capacity: 6,000 MTPA
  • Funding: Primarily through internal accruals
  • Location: Existing carbon black facility at Mahistikry
  • Commissioning: Expected by Q4 FY28
  • Note: Overall carbon black capacity remains unchanged at 2,50,000 MTPA (converted from existing stream)
  • Applications: Engineering plastics, conductive applications, fiber industry, EV & energy storage

Subsidiary Information

The consolidated financial results include 15 subsidiaries:

  • AAT Global Limited (wholly owned)
  • Shandong Dawn Himadri Chemical Industry Limited
  • Himadri Agro Tech Specialities Limited
  • Himadri Clean Energy Limited
  • Himadri Future Material Technology Limited
  • Himadri Green Technologies Innovation Limited
  • Invati Creations Private Limited
  • Himadri Speciality Inc.
  • Birla Tyres Limited (wholly owned from April 07, 2025)
  • Himadri Birla Tyre Manufacturer Private Limited
  • Himadri Advance New Energy Material Limited
  • Trancemarine and Confreight Logistics Private Limited
  • Sturdy Niketan Private Limited
  • Himadri Integrated Minerals and Resources Limited

Auditor Review

  • Auditor: Singhi & Co., Chartered Accountants
  • Review Type: Limited review of unaudited financial results
  • Conclusion: No material misstatement found in financial results
  • Foreign Subsidiaries: 3 foreign subsidiaries not reviewed by Indian auditors due to different accounting standards

Share Capital Update

  • ESOP Allotment: 19,000 equity shares allotted on 6 July 2026 under Himadri Employee Stock Option Plan 2016
  • Resulting Capital: Increased from 50,45,41,599 to 50,45,60,599 equity shares of face value Re. 1 each

Board Meeting Details

  • Date: 15 July 2026
  • Timing: 11:30 a.m. to 3:25 p.m. (IST)
  • Approved by: Board of Directors and Audit Committee